Tenax's TNX-103 misses primary endpoint in Phase 3 LEVEL trial for PH-HFpEFAug 10Clinical readoutTenax Therapeutics, Inc.TNX-103
Tenax reports Q2 2026 results, confirms August LEVEL trial data and ESC presentationJul 31Quarterly updateTenax Therapeutics, Inc.
Tenax to present Phase 3 LEVEL trial data at ESC Congress 2026, expects topline results in AugustJul 2Clinical readoutTenax Therapeutics, Inc.
Sign inSign in